Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Pringy, France Clinical Trials

A listing of Pringy, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (35) clinical trials

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

All Medtronic market-released leads and all market-released IPG, ICD and CRT devices are eligible to be included in this study.

Phase N/A

0.0 miles

Learn More »

Avoidable Readmissions For Patients Hospitalized With Community-Acquired Pneumonia

I. Objectives The purpose of this study is to develop an administrative data-based risk prediction model for identifying potentially avoidable 30-day readmissions of patients hospitalized with community-acquired pneumonia (CAP). The focus is on potentially avoidable readmissions because not all hospital readmissions can be influenced by interventions designed to decrease them. ...

Phase N/A

0.0 miles

Learn More »

Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)

The trial will enroll 194 previously untreated DLBCL patients over 20 months, with the objective to send to the local investigator an extensive molecular tumor characterization by D38 in at least 80% of enrolled patients. The feasibility and efficiency will be demonstrated by deploying and operating a nation-wide network of ...

Phase N/A

0.0 miles

Learn More »

Entyvio (Vedolizumab) Long Term Safety Study

The drug being tested in this prospective, observational study is called vedolizumab. Vedolizumab is being used to treat people who have UC or CD. This study will look at the long-term safety of vedolizumab versus other biologic agents in participants with UC or CD. The study will enroll approximately 5000 ...

Phase N/A

0.0 miles

Learn More »

Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice

This is an observational, multicenter study in patients treated with nivolumab for the approved indications of melanoma and lung cancer in Australia, the EU, Switzerland, and the United States (US). Targeted countries in the EU for study participation include Austria, Belgium, France, Germany, Italy, Spain, and the United Kingdom (UK). ...

Phase N/A

0.0 miles

Learn More »

An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice

This study, a national, multicenter, observational, ambispective, non-interventional study, will be conducted in French hospitals prescribing pomalidomide and already participating in the ongoing Imnovid registry. This study will add to the registry. Indeed, pomalidomide-prescribing physicians and pharmacists dispensing pomalidomide have to enter into the Imnovid registry all patients who have ...

Phase N/A

0.0 miles

Learn More »

Screening Anti-Fungal Exposure in Intensive Care Units

Adequate antifungal therapy is a critical determinant of survival in patients admitted to an Intensive Care Unit (ICU) with suspected or proven fungal infections. Critical illness can alter the way human body handles antifungal agents, i.e. how the drugs are distributed in the body and removed from the body. Consequently, ...

Phase N/A

0.0 miles

Learn More »

Product Surveillance Registry

The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge ...

Phase N/A

0.0 miles

Learn More »

A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care

This is a non-interventional, multicenter, prospective registry of patients with a confirmed diagnosis of adenocarcinoma of the prostate presenting with mCRPC, based on documented metastatic prostate cancer and documented castration resistance. Castrate-resistant prostate cancer is defined by disease progression despite testosterone <50 ng/dL, and/or androgen deprivation therapy, and/or a history ...

Phase N/A

0.0 miles

Learn More »